Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of a FGFR3-TACC3 fusion in esophageal cancer.
Mizukami T, Sakai K, Naruki S, Taniyama T, Horie Y, Izawa N, Tsuda T, Fujino T, Boku N, Yasuda H, Fukunaga T, Nakajima TE, Nishio K. Mizukami T, et al. Among authors: boku n. Ann Oncol. 2017 Feb 1;28(2):437-438. doi: 10.1093/annonc/mdw550. Ann Oncol. 2017. PMID: 27771611 Free article. No abstract available.
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.
Komori A, Hironaka S, Kadowaki S, Mitani S, Furuta M, Kawakami T, Makiyama A, Takegawa N, Sugiyama K, Hirano H, Ando T, Matsushima T, Chida A, Kashiwada T, Komoda M, Matsumoto T, Oda H, Yabusaki H, Kawakami H, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K; West Japan Oncology Group (WJOG). Komori A, et al. Among authors: boku n. Gastric Cancer. 2024 Dec 31. doi: 10.1007/s10120-024-01579-2. Online ahead of print. Gastric Cancer. 2024. PMID: 39738793
Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study).
Kita R, Yasufuku I, Takahashi N, Mizusawa J, Sano Y, Fukuda H, Kurokawa Y, Boku N, Terashima M, Yoshikawa T; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Kita R, et al. Among authors: boku n. Jpn J Clin Oncol. 2024 Dec 18:hyae174. doi: 10.1093/jjco/hyae174. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39690810
Concentrations of Irinotecan and SN-38 in the Ascites and the Fluid Product of Cell-Free and Concentrated Ascites Reinfusion Therapy 9 Days After Administration of Irinotecan in a Patient with Gastric Cancer: A Case Report.
Baba K, Tanie T, Matsubara Y, Hirata Y, Ikematsu H, Imamura CK, Boku N. Baba K, et al. Among authors: boku n. Onco Targets Ther. 2024 Nov 20;17:1089-1094. doi: 10.2147/OTT.S486272. eCollection 2024. Onco Targets Ther. 2024. PMID: 39588517 Free PMC article.
Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Murakami M, Miyata Y, Nakashima K, Abe M, Nishimura J, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakamura N, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Nakajima TE. Murakami M, et al. Among authors: boku n. Int J Clin Oncol. 2025 Jan;30(1):27-39. doi: 10.1007/s10147-024-02663-4. Epub 2024 Nov 21. Int J Clin Oncol. 2025. PMID: 39570460
Authors' reply to 'RE: A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group'.
Nishina T, Boku N, Kurokawa Y, Sasaki K, Machida R, Yoshikawa T. Nishina T, et al. Among authors: boku n. Jpn J Clin Oncol. 2025 Jan 8;55(1):89-90. doi: 10.1093/jjco/hyae149. Jpn J Clin Oncol. 2025. PMID: 39558684 No abstract available.
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.
Nakashima K, Harashima S, Kaneko R, Tanaka R, Abe M, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Satomi E, Takeda M, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Sasaki H. Nakashima K, et al. Among authors: boku n. Int J Clin Oncol. 2025 Jan;30(1):17-26. doi: 10.1007/s10147-024-02652-7. Epub 2024 Nov 12. Int J Clin Oncol. 2025. PMID: 39531096
Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer.
Yamada Y, Nagashima K, Azuma M, Masutani M, Ichikawa H, Iwasa S, Takahashi N, Hirano H, Kanato K, Machida N, Kinoshita T, Hata H, Kawakami H, Takahari D, Boku N, Kurokawa Y, Terashima M, Yoshikawa T, Sekine S, Hiraoka N. Yamada Y, et al. Among authors: boku n. BJC Rep. 2024 Mar 5;2(1):18. doi: 10.1038/s44276-024-00046-w. BJC Rep. 2024. PMID: 39516666 Free PMC article.
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study).
Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Aoki K, Boku N. Shoji H, et al. Among authors: boku n. J Immunother Cancer. 2024 Nov 3;12(11):e010174. doi: 10.1136/jitc-2024-010174. J Immunother Cancer. 2024. PMID: 39489543 Free PMC article.
511 results